Gulf International Bank UK Ltd Has $2.85 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Gulf International Bank UK Ltd reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,504 shares of the medical research company’s stock after selling 155 shares during the quarter. Gulf International Bank UK Ltd’s holdings in IQVIA were worth $2,850,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. FMR LLC raised its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Impax Asset Management Group plc raised its stake in shares of IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after purchasing an additional 157,809 shares during the last quarter. Nordea Investment Management AB raised its stake in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of IQVIA by 3.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after purchasing an additional 39,772 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Up 1.3 %

NYSE:IQV opened at $188.89 on Friday. The company has a market cap of $33.26 billion, a P/E ratio of 25.19, a P/E/G ratio of 1.99 and a beta of 1.48. The stock’s fifty day moving average price is $199.13 and its two-hundred day moving average price is $214.96. IQVIA Holdings Inc. has a 1 year low of $184.66 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insiders Place Their Bets

In related news, Director John G. Danhakl bought 1,275 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on IQV shares. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Bank of America lowered their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. UBS Group reduced their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. reduced their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.